Natera stock heads into results after 12.12% retreat
Published on 11/05/2026 at 16:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors are watching
- Natera will release third-quarter results for the period ended September 30 after the US market closes on November 5.
- Management has scheduled a conference call for 4:30 p.m. ET on the same day.
- The update will give investors a fresh view of demand across oncology, women's health and organ health testing.
Natera stock heads into a scheduled earnings event after the company said it will release third-quarter results after the US market closes on Thursday, November 5. The quote was 12.12 percent below the EUR 374.45 level shown in the October 30 report, creating a fresh market reference before the update.
Natera said in its official announcement that the report covers the quarter ended September 30, 2026. The company also scheduled a conference call and webcast for 4:30 p.m. ET on November 5.
Results will test operating momentum
The release should give investors updated information on Natera's business in oncology, women's health and organ health. The company describes itself as a provider of cell-free DNA and precision-medicine testing, with Signatera among its oncology-focused offerings.
Natera stock traded at 329.05 euros on Lang & Schwarz at 4:00 p.m. CET on Thursday, November 5, 2026. Investors can follow the real-time quote of Natera stock.
Natera stock facts
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Quote: 329.05 euros
- Venue: Lang & Schwarz
- Quote time: 4:00 p.m. CET, Thursday, November 5, 2026
US healthcare and biotechnology shares remain sensitive to clinical, reimbursement and earnings updates, making Natera's release the next scheduled catalyst for investors.
Current market reports provide the broader US equity context.
